Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors

Bibliography

• Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9
   PubMed Web of Science ®Google Scholar
• Giustina A, Zaltieri G, Negrini F, et al. The pharmacological aspects of the treatment of acromegaly. Pharmacol Res 1996;34(5-6):247-68
   PubMed Web of Science ®Google Scholar
• Deghenghi R. Somatostatin analogues in the treatment of the carcinoid syndrome. Biomed Pharmacother 1988;42:585-8
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996;334:246-54
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Nuno M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments- a meta-analysis. J Clin Endocrinol Metab 2014;99:1825-33
   PubMed Web of Science ®Google Scholar
• Grasso LF, Pivonello R, Colao A. Investigational therapies for acromegaly. Expert Opin Investig Drugs 2013;22:955-63
   PubMed Web of Science ®Google Scholar
• Gola M, Bonadonna S, Mazziotti G, et al. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006;29:86-93
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143:4123-30
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 2014;52(3):R223-40
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Sheppard MC, Stephens JM, et al. Clinical, quality of life, and economic value of acromegalic disease control. Pituitary 2011;14:284-94
   PubMed Web of Science ®Google Scholar
• Tuvia S, Pelled D, Marom K, et al. A Novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Chieffo C, Bai SA, et al. A subcutaneous octreotide hydrogel implant for the treatment of acromegay. Endocr Pract 2012;18:870-81
   PubMed Web of Science ®Google Scholar
• Guillemin R. Peptides in the brain: the new endocrinology of the neuron. Science 1978;202:390-402
   PubMed Web of Science ®Google Scholar
• Mandarino L, Stenner D, Blanchard W, et al. Selective effects of somatostatin-14, 25 and -28 on in vitro insulin and glucagonsecretion. Nature 1981;291:76-7
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-42
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98
   PubMed Web of Science ®Google Scholar
• Sims SM, Lussier BT, Kraicer J. Somatostatin activates an inwardly rectifying K+ conductance in freshly dispersed rat somatotrophs. J Physiol 1991;441:615-37
   PubMed Web of Science ®Google Scholar
• Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 2001;35:1-23
   PubMed Web of Science ®Google Scholar
• Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726-35
   PubMed Web of Science ®Google Scholar
• Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 1995;136:4174-81
   PubMed Web of Science ®Google Scholar
• Cerovac V, Monteserin-Garcia J, Rubinfeld H, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010;70:666-74
   PubMed Web of Science ®Google Scholar
• Pagotto U, Arzberger T, Ciani E, et al. Inhibition of Zac1, a new gene differentially expressed in the anterior pituitary, increases cell proliferation. Endocrinology 1999;140:987-96
   PubMed Web of Science ®Google Scholar
• Rocheville M, Lange DC, Kumar U, et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000;275:7862-9
   PubMed Web of Science ®Google Scholar
• Patel PC, Barrie R, Hill N, et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 1994;116:1148-52
   PubMed Web of Science ®Google Scholar
• Adams RL, Adams IP, Lindow SW, et al. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 2005;92:1493-8
   PubMed Web of Science ®Google Scholar
• Badway AC, Blake AD. Somatostatin: a hormone for the heart? Curr Vasc Pharmacol 2005;3:125-31
   PubMedGoogle Scholar
• Morini M, Villa V, Arena S, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003;144:1574-84
   PubMed Web of Science ®Google Scholar
• Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-97
   PubMed Web of Science ®Google Scholar
• Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994;78:398-403
   PubMed Web of Science ®Google Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355:2558-73
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41
   PubMedGoogle Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75
   PubMed Web of Science ®Google Scholar
• Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95-102
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Cavagnini F, et al. Acromegaly treatment consensus workshop participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94:1509-17
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014;10:243-8
   PubMed Web of Science ®Google Scholar
• Giustina A, Bronstein MD, Casanueva FF, et al. Current management practices for acromegaly: an international survey. Pituitary 2011;14:125-33
   PubMed Web of Science ®Google Scholar
• Giustina A, Karamouzis I, Patelli I, et al. Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother 2013;14:2433-47
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985;313(25):1576-80
   PubMed Web of Science ®Google Scholar
• Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 1990;71:391-7
   PubMed Web of Science ®Google Scholar
• Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-8
   PubMed Web of Science ®Google Scholar
• Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711-18
   PubMed Web of Science ®Google Scholar
• Christensen SE, Weeke J, Orskov H, et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf) 1987;27:297-306
   PubMed Web of Science ®Google Scholar
• Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-7
   PubMed Web of Science ®Google Scholar
• Coy DH, Taylor JE. Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism 1996;45(8 Suppl 1):21-3
   PubMed Web of Science ®Google Scholar
• Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45:836-44
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150:489-95
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151:317-24
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150:473-80
   PubMed Web of Science ®Google Scholar
• Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151:439-46
   PubMed Web of Science ®Google Scholar
• Bex M, Abs R, T’Sjoen G, et al. AcroBel -the Belgian registry on acromegaly: a survey of the ’real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol 2007;157:399-409
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95:3141-8
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009;161:331-8
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Pasireotide Acromegaly Study Group. J Clin Endocrinol Metab 2010;95:2781-9
   PubMed Web of Science ®Google Scholar
• Petersenn S, Farrall AJ, Block C, et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary 2013;17:132-40
   Web of Science ®Google Scholar
• Colao A, Bronstein M, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014;99:791-9
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad, somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-16
   PubMed Web of Science ®Google Scholar
• Tulipano G, Bonfanti C, Milani G, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001;73:344-51
   PubMed Web of Science ®Google Scholar
• van der Hoek J, de Herder WW, Feelders RA. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-45
   PubMed Web of Science ®Google Scholar
• Dietrich H, Hu K, Ruffin M, et al. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. Eur J Endocrinol 2012;166:821-8
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein M, Brue T, et al. Phase III, multicenter, randomized study (PAOLA) demonstrating that pasireotide LAR has superior efficacy over octreotide LAR and lanreotide Autogel in patients with inadequately controlled acromegaly. ICE/ENDO Meeting; 21 – 24 June 2014; Chicago, IL, USA
   Google Scholar
• Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011;22:499-506
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013;98:3446-53
   PubMed Web of Science ®Google Scholar
• Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine 2012;42:366-74
   PubMed Web of Science ®Google Scholar
• Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003;26:1242-7
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013;16:294-302
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94:1500-8
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Bogazzi F, et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 2011;164:341-7
   PubMed Web of Science ®Google Scholar
• Arosio M, Macchelli S, Rossi CM, et al. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995;133:430-9
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Orsi E, Giavoli C, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 2003;26:533-8
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brue T, Colao A, et al. Exploratory data evaluating of pasireotide on GH, IGF-1, IGFBP-2, IGFBP-3, HbA1c and Glucose in Patients withInadequately Controlled Acromegaly Enrolled in a 24-Week Study (PAOLA). ICE/ENDO Meeting; 21 – 24June 2014; Chicago, IL, USA
   Google Scholar
• Afargan M, Janson ET, Gelerman G, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001;142:477-86
   PubMed Web of Science ®Google Scholar
• Shimon I, Rubinek T, Hadani M, et al. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J Endocrinol Invest 2004;27:721-7
   PubMed Web of Science ®Google Scholar
• Plöckinger U, Hoffmann U, Geese M, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol 2012;166:223-34
   PubMed Web of Science ®Google Scholar
• Aspireo Pharma website. Available from: http://www.aspireopharma.com/somatoprim [Last accessed 11 May 2014]
   Google Scholar
• ITF2984 Repeated Doses Study in Healthy Volunteers (MAD). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01871844 [Last accessed 11 May 2014]
   Google Scholar
• Phase II Study With ITF2984 in Acromegalic Patients (POC). Available from: http://www.clinicaltrials.gov/ct2/show/NCT02111044 [Last accessed 11 May 2014]
   Google Scholar
• Erfani Jabarian L, Rouini MR, Atyabi F, et al. In vitro and in vivo evaluation of an in situ gel forming system for the delivery of PEGylated octreotide. Eur J Pharm Sci 2013;48:87-96
   PubMed Web of Science ®Google Scholar
• Q Chip Ltd. Drug delivery company [Cardiff, UK]. Available from: http://www.q-chip.com. [Last accessed 11 May 2014]
   Google Scholar
• Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs 2014;19:79-97
   PubMed Web of Science ®Google Scholar
• Roberts J, Linden M, Cervin C, et al. Randomized study demonstrating that octreotide fluid crystal provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR (Sandostatin LAR) in healthy volunteers. ICE/ENDO Meeting; 21 – 24 June 2014; Chicago, IL, USA
   Google Scholar
• CAM2029: new ready-to-use, long-acting octreotide product for treatment of acromegaly and carcinoid tumours. Avilable from http://www.camurus.com/index.asp?DocumentIDSub=3&DocumentID=2&ShowSub=(2)&Show=(3)&main=Products [Last accessed 11 May 2014]
   Google Scholar
• Drewe J, Fricker G, Vonderscher J, et al. Enteral absorption of octreotide: absorption enhancement by polyoxyethylene- 24-cholesterol ether. Br J Pharmacol 1993;108:298-303
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Marbach P, et al. Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci 2000;89:951-7
   PubMed Web of Science ®Google Scholar
• Dorkoosh FA, Verhoef JC, Verheijden JH, et al. Peroral absorption of octreotide in pigs formulated in delivery systems on the basis of superporous hydrogel polymers. Pharm Res 2002;19:1532-6
   PubMed Web of Science ®Google Scholar
• Tuvia S, Salama P, Weinstein I, et al. Octreolin a safe oral alternative for parenteral octreotide treatment. Growth Horm IGF Res 2010;20:S35-6
   Google Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012;97:2362-9
   PubMed Web of Science ®Google Scholar
• Melmed S, Popovic-Brkic V, Bidlingmaier M, et al. Efficacy and safety of oral octreotide in acromegaly: results of a multicenter phase III trial in 155 patients. ICE/ENDO Meeting; 21 – 24 June 2014; Chicago, IL, USA
   Google Scholar
• Maggio ET, Grasso P. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. Regul Pept 2011;167:233-8
   PubMed Web of Science ®Google Scholar
• Aegis Hydrogel™ and ProTek® Technology. Avilable from http://aegisthera.com/technology/#protek [Last accessed 11 May 2014]
   Google Scholar
• Chieffo C, Cook D, Xiang Q, et al. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab 2013;98:4047-54
   PubMed Web of Science ®Google Scholar
• Marazuela M, Ramos-Leví A, Sampedro-Núñez M, et al. Cabergoline treatment in acromegaly: pros. Endocrine 2014;46:215-19
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Gadelha MR. Cabergoline treatment in acromegaly: cons. Endocrine 2014;46:220-5
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 2010;21:123-33
   PubMed Web of Science ®Google Scholar
• Saveanu A, Jaquet P. Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 2009;10:83-90
   PubMed Web of Science ®Google Scholar
• Jaquet P, Gunz G, Saveanu A, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005;28:21-7
   PubMedGoogle Scholar
• Culler MD. Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Horm Metab Res 2011;43:854-7
   PubMed Web of Science ®Google Scholar
• Baudin E. Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab 2007;3:228-39
   PubMedGoogle Scholar
• Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72
   PubMed Web of Science ®Google Scholar
• Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-76
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the pancreas [chapter 12]. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. IARC; Lyon: 2010 p. 322-6
   Google Scholar
• Travis WD. Lung tumors with neuroendocrine differentiation. Eur J Cancer 2009;45:1:251-66
   PubMedGoogle Scholar
• Oberg KE, Reubi JC, Kwekkeboom DJ, et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;39:742-53
   Google Scholar
• Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427
   PubMed Web of Science ®Google Scholar
• Öberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine 2012;42:3-4
   PubMed Web of Science ®Google Scholar
• Wulbrand U, Wied M, Zofel P, et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998;28:1038-49
   PubMed Web of Science ®Google Scholar
• de Herder WW, Hofland LJ, van der Lely AJ, et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003;10:451-8
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine 2012;41:40-52
   PubMed Web of Science ®Google Scholar
• Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-6
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 2001;47:1-29
   PubMed Web of Science ®Google Scholar
• Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1412-17
   PubMed Web of Science ®Google Scholar
• Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005;152:757-67
   PubMed Web of Science ®Google Scholar
• Scarpignato C. The place of octreotide in the medical management of the dumping syndrome. Digestion 1996;57:114-18
   PubMed Web of Science ®Google Scholar
• He X, Wang J, Wu X, et al. Pancreatic somatostatinoma manifested as severe hypoglycemia. J Gastrointestin Liver Dis 2009;18:221-4
   PubMed Web of Science ®Google Scholar
• Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998;42:792-4
   PubMed Web of Science ®Google Scholar
• Schwartz CJ, Kimberg DV, Sheerin HE, et al. Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa. J Clin Invest 1974;54:536-44
   PubMed Web of Science ®Google Scholar
• Tulipano G, Stumm R, Pfeiffer M, et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004;279:21374-82
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
   PubMed Web of Science ®Google Scholar
• Eriksson B, Öberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999;10:S31-8
   PubMed Web of Science ®Google Scholar
• Öberg K. Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:833-41
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63
   PubMed Web of Science ®Google Scholar
• Clark OH, Benson AB III, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw 2009;7:712-47
   PubMed Web of Science ®Google Scholar
• Caplin M, Ruszniewski P, Pavel M, et al. A randomized, double-blind, placebo-controlled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET) [abstract 3]. European Cancer Congress 2013; 28 September 2013, Amsterdam, NL
   Google Scholar
• Caplin ME, Ruszniewski P, Pavel M, et al. Lanreotide Autogel/depot shows antitumor effects in patients with metastatic enteropancreatic NETs: results of the Clarinet Extension Study. ICE/ENDO Meeting; 21 – 24June 2014; Chicago, IL, USA
   Google Scholar
• Prommegger R, Bale R, Ensinger C, et al. Gastric carcinoid type I tumour: new diagnostic and therapeutic method. Eur J Gastroenterol Hepatol 2003;15:705-7
   PubMed Web of Science ®Google Scholar
• Fykse V, Sandvik AK, Qvigstad G, et al. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004;39:621-8
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Caletti GC, et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000;343:551-4
   PubMed Web of Science ®Google Scholar
• Wang S, Bao Z, Liang QM, et al. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3beta, A Wnt/beta-catenin pathway modulator. Hepatogastroenterology 2013;60:1639-46
   PubMed Web of Science ®Google Scholar
• Yim KL. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine 2011;40:181-6
   PubMed Web of Science ®Google Scholar
• Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol 1991;79:74-7
   PubMed Web of Science ®Google Scholar
• Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992;3:35-41
   PubMedGoogle Scholar
• Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-93
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761-71
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors–the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689-96
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012;18:1777-89
   PubMed Web of Science ®Google Scholar
• Breuleux M, Klopfenstein M, Stephan C, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009;8:742-53
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8
   PubMed Web of Science ®Google Scholar
• Moreno A, Akcakanat A, Munsell MF, et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008;15:257-66
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378(9808):2005-12
   PubMed Web of Science ®Google Scholar
• Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107-12
   PubMed Web of Science ®Google Scholar
• Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of t he digestive system during treatment with somatostatin analogs. Acta Oncol 1997;36:607-14
   PubMed Web of Science ®Google Scholar
• Lesche S, Lehmann D, Nagel F, et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009;94:654-61
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286:69-74
   PubMed Web of Science ®Google Scholar
• Kvols L, Wiedenmann B, Oberg K, et al. The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study [abstract 171]. ASCO GI Cancers Symposium, S. Francisco, CA, USA; 2006
   Google Scholar
• Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 2012;19:657-66
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of pasireotide long acting release vs. octreotide long acting release in patients with metastatic carcinoid disease. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00690430 [Last accessed 11 May 2014]
   Google Scholar
• Wolin EM, Jarzab B, Eriksson B, et al. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. J Clin Oncol 2013;31(Suppl):abstract 4031 (2013 ASCO Annual Meeting)
   Google Scholar
• 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01563354 [Last accessed 11 May 2014]
   Google Scholar
• Kidd M, Modlin IM, Black JW, et al. A comparison of the effects of gastrin, somatostatin and dopamine receptor analogs on rat gastric enterochromaffin-like cell secretion and proliferation. Regul Pept 2007;143:109-17
   PubMed Web of Science ®Google Scholar
• Sharif N, Gendron L, Wowchuk J, et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007;148:2095-105
   PubMed Web of Science ®Google Scholar
• Baragli A, Alturaihi H, Watt HL, et al. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2. Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 2007;19:2304-16
   PubMed Web of Science ®Google Scholar
• O’Toole D, Saveanu A, Couvelard A, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 2006;155:849-57
   PubMed Web of Science ®Google Scholar
• Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005;20:1837-44
   PubMed Web of Science ®Google Scholar
• Maison P, Tropeano AI, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007;92:1743-7
   PubMed Web of Science ®Google Scholar
• De Marinis L, Bianchi A, Mazziotti G, et al. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 2008;11:13-20
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 2013;98:3402-10
   PubMed Web of Science ®Google Scholar
• Mancini T, Porcelli T, Giustina A. Treatment of cushing disease: overview and recent findings. Ther Clin Risk Manag 2010;6:505-16
   PubMed Web of Science ®Google Scholar
• Giustina A, Ambrosio MR, Beck-Peccoz P, et al. Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest 2014; DOI:10.1007/s40618-014-0114-5
   PubMed Web of Science ®Google Scholar
• Boyd AE, DeFord LL, Mares JE, et al. Improving the success rate of gluteal intramuscular injections. Pancreas 2013;42:878-82
   PubMed Web of Science ®Google Scholar
• Salvatori R, Nachtigall LB, Cook DM, et al. SALSA Study Group. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary 2010;13:115-22
   PubMed Web of Science ®Google Scholar